Key Highlights

  • Remote patient monitoring subscription accrual Revenue was A$539,000, up 12.5% on Q4 FY26, the fifth consecutive quarter of record RPM revenue.
  • Customer cash receipts were A$544,000, up 33% quarter on quarter, including a A$257,917 receipt from the AstraZeneca Arrival study.
  • The company added 1,033 device shipments and 900 device activations in the quarter.
  • John Perry was appointed interim Chief Executive Officer as the company moves into its value-based care growth phase.

Adherium Limited (ASX:ADR) released its Appendix 4C and quarterly activities report on 30 October 2026, covering the quarter ended 30 September 2026. The digital respiratory management company, which develops the Hailie Sensor and Smartinhaler platform, reported growth in remote patient monitoring revenue and customer cash receipts, and a Leadership change to support its value-based care growth phase.

Revenue and Cash Receipts

Remote patient monitoring subscription accrual revenue was A$539,000, up 12.5% from A$479,000 in the prior quarter, marking the fifth consecutive quarter of record RPM revenue. Customer cash receipts were A$544,000, up 33% quarter on quarter from A$408,000.

The cash receipts figure includes an AstraZeneca Arrival study payment of A$257,917 received on 9 October 2026. The company said device shipments remain the lead indicator of recurring revenue, with billable revenue recognised as patients are activated.

Device Shipments and Activations

In the quarter, the company added 1,033 device shipments and 900 device activations, bringing cumulative totals to 6,392 shipments and 4,732 activations. The company said billable revenue is recognised as patients are activated.

After the quarter, Adherium partnered with Florida Lung, Asthma and Sleep Specialists, which the company said extends the reach of its Hailie platform into Central Florida.

The company's device model depends on shipments to patients and clinics, and the report notes that shipments are the lead indicator while billable revenue follows activation. The quarter's shipments and activations both rose, which the company presents as continued growth in its device base. The cumulative totals, 6,392 shipments and 4,732 activations, give a longer-term view of the installed base than the quarterly figures alone.

Leadership and Cash Flow

John Perry was appointed interim Chief Executive Officer, as announced on 29 July 2026, to lead the company's transition into its value-based care growth phase. The quarterly Cash Flow report shows an operating outflow of about A$3.5 million, with staff costs of A$2.1 million and administration and corporate costs of A$1.5 million.

The company's opening cash balance for the quarter was A$1.4 million. The company's Hailie Care product is not approved for commercial Supply in Australia, and clinical data referenced in the report is preliminary.

Sector Context and Risks to Watch

Remote patient monitoring companies depend on hospital, clinic and payer adoption, and on the rate at which devices are activated and remain in use. Revenue recognition for these platforms follows patient activity rather than shipments, which is why the company tracks both figures.

The main risks identified in the report are the operating cash outflow relative to the company's cash balance, the regulatory status of Hailie Care in Australia, and the pace of U.S. adoption. Future quarterly reports will show whether activations continue to grow and whether cash receipts keep pace with spending.

Final Word

Adherium reports record Recurring Revenue and growing device activations, alongside an operating cash outflow that is large relative to its cash balance. The next quarter is expected to show whether activations and receipts keep rising and how the leadership transition progresses.